The Economist | Dec 3rd 2011 | NEW YORK | from the print edition
FOR some years the big
drugmakers have been dreading an approaching “patent cliff”—a slump in sales as
the patents on their most popular pills expire or are struck down by legal
challenges, with few new potential blockbusters to take their place.